Physician profile
Gary Fishman
NPI 1831138304
$2,492.66
in general payments reported to CMS, 2019-2025
23 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $215 · 2021: $73.95 · 2022: $561 · 2023: $304 · 2024: $383 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $687.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $425.78 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $415.80 | 2019-2025 | Dupixent |
| Intersect Ent, INC. | $136.23 | 2019-2022 | |
| Boston Scientific Corporation | $118.92 | 2024 | |
| Medtronic, INC. | $93.93 | 2024-2025 | Propel, Sinuva |
| Optinose US, INC. | $78.71 | 2020-2022 | |
| Kaleo, INC. | $73.75 | 2019-2022 | |
| Pfizer INC. | $71.38 | 2019-2021 | |
| Alk-Abello, INC | $56.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.79 | 2022 | |
| Neurent Medical Limited | $44.00 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Novartis Pharmaceuticals Corporation | $40.69 | 2022 | |
| Medtronic USA, INC. | $33.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $23.61 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.28 | 2022 | |
| Biocryst US Sales Co., LLC | $22.15 | 2022 | |
| Biotissue Holdings INC. | $20.22 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.86 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Aerin Medical INC. | $13.67 | 2025 | |
| Smith+Nephew, INC. | $12.98 | 2023 | Coblation, Rapid Rhino |
| Circassia INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.